Humanized Anti-IL-5 Antibody Therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27104969.
- Also identified by DOI 10.1016/j.cell.2016.04.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil growth, activation, and survival factor. Humanized anti-IL-5 antibodies are effective in treating asthma patients with the severe eosinophilic form of the disease and are the first new class of asthma drugs approved in 12 years.